International Collaborative Gaucher Group (ICGG) Gaucher Registry
Phase of Trial: Phase IV
Latest Information Update: 04 Jul 2019
Price : $35 *
At a glance
- Drugs Alglucerase (Primary) ; Imiglucerase (Primary)
- Indications Gaucher's disease; Gaucher's disease type I
- Focus Therapeutic Use
- Sponsors Sanofi Genzyme
- 07 Jun 2019 Planned End Date changed from 31 Jan 2030 to 31 Jan 2034.
- 07 Jun 2019 Planned primary completion date changed from 31 Jan 2030 to 31 Jan 2034.
- 01 Sep 2017 Results (Data cut off 4 March 2016; n=2069) of an analysis assessing prevalence of severe clinical manifestations in Gaucher disease type 1 (GD1) patients at the time of treatment initiation since alglucerase/imiglucerase approval in USA, published in the American Journal of Hematology